Accretive Health, Inc. (ACHI) –
-
Achiko AG Company Update
-
Achiko AG Production and Sales Update
-
2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders Adopt All Proposals
-
Achiko AG Issues a Convocation Notice to its Shareholders for its Annual General Meeting on December 20, 2022
-
Achiko AG Announces Corporate Update Webcast
-
Achiko AG Commences Commercial Deliveries in Indonesia
-
Achiko AG Production and Company Update
-
Achiko AG Appoints New Chief Financial Officer
-
Achiko AG Reports First Half to June 30, 2022 Results and Provides Corporate Update as of September 30, 2022
-
Achiko AG – Investor Briefing
-
Achiko AG – Suspension of Trading
-
Achiko AG Announces Annual Results for the Year Ended December 31, 2021
-
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 26, 2022
-
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 20, 2022
-
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 10, 2022
-
Achiko AG Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 6, 2022
-
Achiko Secures $1.3 Million Financing with Strategic Investors Buranto AG and Negma Group
-
Achiko AG Reports Key Unaudited Financial Results for the Year Ended December 31, 2021
-
Achiko AG Obtains CE Mark for AptameX™ Covid-19 Rapid Test
-
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by May 31, 2022
-
AptameX Production and Commercialization Update
-
Achiko AG Signs Major Marketing and Sales Agreement with World’s Largest Islamic Association for its AptameX Covid-19 Rapid Test
-
Achiko Secures up to USD$12.6 Million Equity and Debt Financing Lines with RiverFort Over Three Years
-
Achiko AG Production and Sales Update
-
Achiko AG Research Paper and Commercialization Update
-
Achiko AG Strengthens Senior Team with Appointment of Head of Corporate Development
-
Achiko AG Announces Feature Article on “How We Get Back to Normal” with its AptameX™ Covid-19 Rapid Test Technology
-
Achiko AG Reports Breakthrough Calibration Results for its AptameX™ Covid-19 Rapid Test Technology
-
Achiko AG Completing CHF4.85m Financing and Changes to Senior Team
-
Achiko AG Looks Back at Pivotal Year and Reaffirms Commitment to Provide Affordable and Accurate COVID-19 Testing Solution
-
Achiko AG’s Shares Begin Trading on the OTCQB Market
-
Achiko’s Commercialization Update: Optimized Second-Generation Covid-19 Diagnostic Test Receives Full Product Registration Approval in Indonesia
-
Achiko’s Position on Omicron Variant
-
Achiko’s Covid-19 DNA Aptamer-Based Rapid Testing Platform Update
-
Achiko Initiates Development of Dengue Diagnostic Test
-
Achiko Secures Initial Sales of AptameX Covid-19 Diagnostic Test
-
Market Outlook and Production Plan Update for AptameX
-
Achiko Launches Covid-19 Testing Pilot Program in Indonesia
-
Achiko’s Rapid Covid-19 Diagnostic Test AptameX™ Receives Product and Registration Approval from Indonesia’s Ministry of Health
-
Achiko Engages EpiMetrics to Expand Covid-19 Testing Operations with Udayana University in Bali, Indonesia in the Implementation of a Mass Testing Program
-
Achiko Working Towards a Solution for Frequent Global Mass COVID-19 Testing
-
Achiko Announces an Extension of its Convertible Loan Transaction with Negma Group
-
Achiko Announces the Successful Integration of its Teman Sehat Digital Ecosystem and AptameX Covid-19 Diagnostic Testing Platform for Launch in Indonesia
-
Achiko AG Announces Successful Integration of its Teman Sehat Digital Ecosystem and AptameX Covid-19 Diagnostic Testing Platform for Launch in Indonesia
-
Achiko Completes Initial Shipment of AptameX, its Progressive Covid-19 Diagnostic Test to Indonesia, Delivering 77% Sensitivity at Low Viral Loads
-
Achiko Appoints New Chief Financial Officer and Announces Changes to Senior Team
-
Achiko’s Joint Venture Partner Obtains a Distribution Certificate for AptameX, a Novel Diagnostic Test for Covid-19 in Indonesia, and Commences Product Registration
-
Achiko Establishes Joint Venture with PT Indonesia Farma Medis for Production and Distribution of its Test Platform for Covid-19 in Indonesia
-
Achiko Concludes Phase 1 Study of Project Gumnuts for Covid-19 Testing
-
Achiko Strengthens Leadership Team with New President and New SVP Commercialization
Back to ACHI Stock Lookup
